ArriVent BioPharma, Inc.

# Signal Note: OrbiMed Initiates $60.9M Position in ArriVent BioPharma OrbiMed's new 3M+ share position signals conviction in ArriVent's clinical pipeline, likely driven by AVB-500 (a dual GLP-1/GIP receptor agonist) advancing toward Phase 2 data in obesity/metabolic disease—a crowded but high-revenue category where differentiation on efficacy, tolerability, or dosing could unlock significant value. The timing suggests confidence in near-term readouts that could de-risk the program or establish competitive positioning ahead of a market with entrenched players. This represents a material allocation from a mega-fund with deep healthcare networks and strong exit track records.